Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

14.18 -0.21 (-1.46%)
Streaming Delayed Price Updated: 11:07 AM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Earnings Outlook For MediWound ↗
 
Via Benzinga
News headline image
MediWound to Report Third Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients 
From MediWound Ltd.
Via GlobeNewswire
News headline image
HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About MediWound ↗
 
Via Benzinga
News headline image
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Deploys NexoBrid® for Emergency Supply
From MediWound Ltd.
Via GlobeNewswire
News headline image
Q4 Stock Predictions: 3 Micro-Cap Stocks Ready to Skyrocket Into 2024 ↗
These Q4 micro-cap stocks are the ones to buy in on for long-term growth and returns to any investor's portfolio. 
Via InvestorPlace
News headline image
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Outlook For MediWound ↗
 
Via Benzinga
News headline image
Recap: MediWound Q1 Earnings ↗
 
Via Benzinga
News headline image
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Outlook For MediWound ↗
 
Via Benzinga
News headline image
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Second Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Commercial Launch of NexoBrid® in Japan
Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement 
From MediWound Ltd.
Via GlobeNewswire
News headline image
5 Analysts Have This to Say About MediWound ↗
 
Via Benzinga
News headline image
3 Micro-Cap Stocks to Buy for Multibagger Returns ↗
These are the micro-cap stocks to buy and they represent companies with decent fundamentals and visibility for robust growth. 
Via InvestorPlace
News headline image
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 30, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter. 
Via Benzinga
News headline image
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces an Additional $10 Million Award from BARDA
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.